Skip to content

Ipilimumab

Yervoy (ipilimumab) is an antibody pharmaceutical. Ipilimumab was first approved as Yervoy on 2011-03-25. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Trade Name Yervoy
Common Name Ipilimumab
Indication colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, renal cell carcinoma
Drug Class Monoclonal antibodies
Ipilimumab
Get full access now